Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

NCT01390792 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 622

Last updated 2017-05-16

No results posted yet for this study

Summary

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Conditions

  • Influenza, Human

Interventions

DRUG

Zanamivir hydrate

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-02-28
Completion
2009-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01390792 on ClinicalTrials.gov